PCPo-Min Chen

Po-Min Chen

*This is an algorithmically generated author record based on publicly available information.

Po-Min Chen has a total of 180 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • 212 Results of single arm, multi-center, two-stage phase II clinical study of thalidomide in Taiwanese patients with myelodysplastic syndrome (MDS)

    by C.-S. Chang, T.-J. Chiou, S.-F. Lin, P.-M. Chen, M.-C. Chang, W.-Y. Kao, T.-Y. Chao, C.-Y. Chung, L.-T. Hsiao, C.-C. Yen, et al.

    • 1 June 2009
      • Vol. 15, 13-6

    Haematopoietic stem cell transplantation in Taiwan: past, present, and future.

    by P M Chen, L T Hsiao, J L Tang, C C Yen, J H Liu, K H Lin, T J Chiou, C H Tzeng

    In Taiwan, haematopoietic stem cell transplantation (HSCT) has been used to treat patients with haematological diseases since 1983. Thereafter till 2007, there were 2537 patients who had undergone HSCT in more than 15 hospitals. Their diseases included acute myeloid leukaemia in 27.8% of cases, non-Hodgkin's lymphoma 23.3%, acute lymphoblastic leukaemia 12.8%, chronic myeloid leukaemia 11.9%, severe aplastic anaemia 8.7%, and multiple myeloma 4.1%. Most of the cases received myeloablative conditioning regimens. More than 15% of cases received non-myeloablative regimens, and the mean age of these cases was at least 10 years older than those who received myeloablative regimens. The types of graft included peripheral blood (60.4%) and bone marrow (32.0%). A total of 35% of patients received autologous grafts. Of 1557 allogeneic HSCT patients, 338 (21.7%) received grafts from unrelated donors. Cord blood transplantation has been successfully performed in paediatric patients with thalassaemia major and with a large body size, and adult patients. The incidence of acute graft-versus-host disease was relatively low in Taiwan. On the contrary, a relatively higher proportion of hepatitis B carrier in the recipients had led to a higher incidence of reactivation hepatitis, which was markedly decreased following lamivudine prophylaxis. In conclusion, HSCT has become a routine therapy for major medical centres in Taiwan. Our unique experiences in the past decades also contributed to the progress of HSCT. With the establishment of professional association and patient supportive groups, we hope we can fully improve our daily practice and clinical as well as basic research in HSCT.


    • 1 June 2009
      • Vol. 15, 42-4

    Hepatitis B infection in haematopoietic stem cell transplantation: still unresolved.

    by L T Hsiao, T J Chiou, J P Gau, J H Liu, C H Tzeng, P M Chen

    Impact of hepatitis B virus (HBV) infection on haematopoietic stem cell transplantation (HSCT) was reported earlier since late 1980s. It was shown that changing patterns of HBV serological markers was accompanied by variable severity of hepatitis after transplantation. Recipient's hepatitis B virus surface antigen (HBsAg) positivity was not considered an absolute contra-indication to allogeneic HSCT. However, HBsAg positivity was an important risk factor of reactivation hepatitis after transplantation, especially in allogeneic setting. Managing HBV reactivation in HSCT recipients was not successful till the availability of lamivudine since mid-1990s. For HBsAg-positive recipients, prophylactic lamivudine has been shown to significantly reduce reactivation hepatitis. As for HBsAg-negative recipients, there have been a small number of patients who develop so-called reverse seroconversion, that is, appearance of HBsAg after transplantation. In addition to chronic graft-versus-host disease, the risk was also high in allogeneic HSCT recipients who received fludarabine-antithymocyte globulin-containing conditioning regimens. The HBV is harboured earlier in the recipients before transplantation rather than transmitted via transfusion. At present, the optimal duration of lamivudine prophylaxis is not well-defined, and there are several fatal cases associated with early withdrawal and resistant HBV mutants. In conclusion, in HBV-endemic areas, the war between HBV and HSCT recipients continued even though several anti-HBV agents and molecular detection techniques are available. It deserves additional effort to overcome and also presents a chance to elucidate underlying mechanisms of HBV immunity, which are not easily studied in non-HSCT setting.


  • Promising overall survival of patients with recurrent/metastatic squamous cell carcinoma of head and neck receiving gemcitabine plus cisplatin treatment: report of a multi-center phase II study

    by Muh-Hwa Yang, Peter Mu-Hsin Chang, Cheng-Hwai Tzeng, Shyue-Yih Chang, Pen-Yuan Chu, Shyh-Kuan Tai, Tung-Lung Tsai, Yi-Feng Wang, Jui-Lin Huang, Hung-Ming Wang, et al.

    The efficacy and safety of gemcitabine in combination with cisplatin (GC) as the first-line treatment in patients with recurrent/metastatic (R/M) squamous cell carcinoma of head and neck (SCCHN) was examined. Patients with R/M SCCHN without prior treatment for their R/M disease were eligible and treated with gemcitabine 1,250 mg/m2 on day 1, day 8 and cisplatin 80 mg/m2 on day 8 every 21 days. Forty patients were enrolled from March 2004 to January 2006, and 30 were evaluable for treatment effectiveness and outcome. The median age of evaluable patients was 50 years and all patients were male. Partial response was observed in 9 (30%) and stable disease in 7 (23.3%) patients. The overall response rate and disease control rate was 30 and 53.3%, respectively. The major toxic effects were ≥grade 3 leukopenia and anemia (65 and 27.5%, respectively). With a follow-up of 72 months, the median time to progression (TTP) was 128 days (95% CI, 78–242) and median overall survival (OS) was 401 days (95% CI, 216 ~not reached). This GC regimen demonstrates a good activity and a promising survival period in patients with R/M SCCHN.


  • Diffusion Capacity Predicts Long-term Survival After Allogeneic Bone Marrow Transplantation for Acute Lymphoblastic Leukemia

    by Peter Mu-Hsin Chang, Tzeon-Jye Chiou, Chueh-Chuan Yen, Liang-Tsai Hsiao, Jin-Hwang Liu, Po-Min Chen

    Sion capacity for carbon monoxide (DLCO) were evaluated before and after allogeneic BMT every 3 months in 32 patients who survived for at least 100 days. General case histories were also examined. Results: Univariate analysis revealed that decreased post-BMT DLCO was associated with increased overall and event-free survival (p <0.05). While a pre-BMT FEV1 of <70% was associated with significantly decreased overall survival (p <0.05), multiple regression analysis indicated that patients without cytomegalovirus (CMV) infection, having limited chronic graft-versus-host disease (GVHD) and with markedly decreased DLCO had better overall survival (p <0.05). After adjusting for age, gender, chronic GVHD, and CMV infection, patients with decreased DLCO exhibited enhanced overall survival. Two-year survival and event-free survival rates were significantly higher in patients with decreased DLCO. Conclusion: We conclude that DLCO may be a good long-term predictor of outcome in patients with ALL following BMT. [J Chin Med Assoc 2008;71(5):234–240] *Correspondence to: Dr Po-Min Chen, Division of Hematology and Oncology, Department of Medicine, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112, Taiwan, R.O.C E-mail: pmchen@vghtpe.gov.tw Received: October 19, 2007; • Accepted: February 5, 2008. © 2008 by Lippincott Williams & Wilkins, Inc....


  • Open Access

    In Reply

    by Wei-Shu Wang, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kae Jiang, Huann-Sheng Wang, Tzeon-Jye Chiou, Jin-Hwang Liu, Chueh-Chuan Yen, Po-Min Chen


  • Open Access

    Oral Glutamine Is Effective for Preventing Oxaliplatin-Induced Neuropathy in Colorectal Cancer Patients

    by Wei-Shu Wang, Jen-Kou Lin, Tzu-Chen Lin, Wei-Shone Chen, Jeng-Kae Jiang, Huann-Sheng Wang, Tzeon-Jye Chiou, Jin-Hwang Liu, Chueh-Chuan Yen, Po-Min Chen

    Learning Objectives: After completing this course, the reader will be able to: Identify the clinical features of oxaliplatin-induced neuropathy.Discuss the current approaches for managing chemotherapy-induced neuropathy.Explain the rationale for using glutamine in preventing oxaliplatin-induced neuropathy.CME Access and take the CME test online and receive 1 AMA PRA Category 1 Credit™ at CME.TheOncologist.com


  • A new model for predicting the timing of leukapheresis on the basis of CD34+ cell and hematopoietic progenitor cell levels

    by Hao-Wei Teng, Liang-Tsai Hsiao, Shu-Chou Chaou, Jyh-Pyng Gau, Tzu-Chi Lee, Ying-Yih Shih, Chun-Yu Liu, Ying-Chung Hong, Ming-Huang Chen, Mu-Hsin Chang, et al.


  • Higher fungal infection rate in elderly patients (more than 80 years old) suffering from diffuse large B cell lymphoma and treated with rituximab plus CHOP

    by Peng-Chan Lin, Liang-Tsai Hsiao, Say-Bee Poh, Wei-Shu Wang, Chueh-Chuan Yen, Ta-Chung Chao, Jin-Hwang Liu, Tzeon-Jye Chiou, Po-Min Chen

    Although adding rituximab to standard cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy is an efficacious and well-tolerated regimen in elderly patients with diffuse large B cell lymphoma (DLBCL), it may increase susceptibility to opportunistic infections, and such cases have been reported. Our study was to identify the risk factors for fungal infection in a retrospective case-control matched study of 34 elderly DLBCL patients treated with rituximab plus CHOP (R-CHOP) and 35 control patients treated with the standard CHOP regimen at the Taipei Veterans General Hospital, Taiwan. The rate of overall infection was similar in both groups. However, subgroup analysis found that the fungal infection rate was significantly different, 41.7 and 17.1%, in the R-CHOP and CHOP groups, respectively, (P = 0.03). Univariate analysis identified the rituximab plus CHOP chemotherapy regimen (P = 0.03), age older than 80 years (P = 0.04), and bone marrow involvement (P = 0.04) as risk factors for development of fungal infection, whereas, multivariate regression analysis identified only rituximab plus CHOP and old age. Adding rituximab to the standard CHOP regimen in elderly DLBCL patients might increase the incidence of fungal infection especially in those older than 80 years old.


  • Sequential Therapy with Capecitabine Followed by Vinorelbine/Cisplatin in Patients with Anthracycline/Taxane-refractory Metastatic Breast Cancer

    by Peng-Chan Lin, Wei-Shu Wang, Muh-Hwa Yang, Chueh-Chuan Yen, Ta-Chung Chao, Liang-Tsai Hsiao, Po-Min Chen

    Background: Currently, there is no standard treatment for patients with anthracycline and taxane-refractory metastatic breast cancer (MBC). Capecitabine or vinorelbine plus cisplatin is an effective palliative regimen for taxane-refractory MBC. In this study, we analyzed the efficacy and toxicity of sequential therapy with capecitabine followed by biweekly vinorelbine plus cisplatin in 37 patients with anthracycline and taxane-refractory MBC in Taipei Veterans General Hospital. Methods: Capecitabine (2,500 mg/m2 twice daily for 2 weeks, followed by 1 week of rest) was repeated every 3 weeks until the disease progressed. Patients then received biweekly vinorelbine (25 mg/m2) plus cisplatin (40 mg/m2) (arm A, n = 17) or best supportive care (BSC) (arm B, n = 20) in accordance with patient preference and clinical judgment. The clinical variables and response to capecitabine were well balanced in both arms. Results: The overall response rate to capecitabine was 32%, with a complete response rate of 5% and a partial response rate of 27%. Stable disease was achieved in an additional 46%. The disease control rate with capecitabine was 78%. Median progression-free survival and overall survival with capecitabine were 5.9 and 9.5 months, respectively. There was a trend toward better overall survival in arm A patients compared with arm B (BSC) patients, though statistical significance was not reached (10.4 vs. 7.4 months; p = 0.08); however, a significantly better overall survival rate was observed in the subgroup with capecitabine-controlled disease (10.8 vs. 6.9 months; p = 0.015). The safety profile of vinorelbine/cisplatin was acceptable: only 6% developed grade 4 neutropenia. Conclusion: We suggest that sequential therapy is not necessarily effective compared with capecitabine alone, but is probably effective in patients initially controllable with capecitabine.